Skip to main content

Videos

The Most Important Advances in Precision Medicine Being Presented at ASCO 2018
Dr David Spigel reviews 3 of the most important, practice-changing topics at ASCO 2018: new therapies targeting RET in a number of tumor types, a prognostic biomarker assay to predict whether patients with breast cancer will need adjuvant hormonal therapy or chemotherapy, and the minimum level of PD-L1 positivity required to predict outcomes with immunotherapy in lung cancer. Read More ›

How Patient-Centric Care is Changing How Cancer Patients are Treated
Dr David Spigel considers how patient-reported outcomes, as well as palliative and supportive care, are revolutionizing cancer care so that consideration is being given to treating the patient, not just the cancer. Read More ›

New Clinical Trial Data Presented at ASCO 2018: How Will it Change How you Practice?
Dr David Spigel discusses the 2 major themes highlighted at ASCO 2018: the use of cancer biomarkers to achieve precision therapy, and fine tuning treatment of patients with immunotherapy with respect to who to treat, how to treat, and how to predict clinical outcomes. Read More ›

Explaining Treatment Regimens to Patients with HR+/HER2- Metastatic Breast Cancer
Dr Thomas Bachelot is careful to set reasonable expectations for his patients with HR+/HER2- metastatic breast cancer regarding how long their treatment will last and how it will impact them. Read More ›

HR+/HER2- Metastatic Breast Cancer: Common Presenting Symptoms
Hope Rugo, MD, discusses common presenting symptoms of HR+/HER2- metastatic breast cancer, citing bone metastasis as the most prevalent. Read More ›

Left- vs Right-Sided Colon Cancers
The WCGIC chairperson, professor Eric Van Cutsem, MD, PhD, heads the Division of Digestive Oncology at University Hospitals Leuven and KU Leuven, Leuven, Belgium. He describes the difference between left- and right-sided colon cancers in terms of prognosis and response to therapy. Read More ›

A Look at SIRT Y-90 and the SARAH Trial
Dr. Valérie Vilgrain discusses SIRT Y-90 and the results of the SARAH trial. Read More ›

Page 6 of 6